IOVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Iovance Biotherapeutics Inc (IOVA) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is undervalued at its current price of $3.79, with strong long-term growth potential driven by its flagship product, Amtagvi, and positive sentiment from analysts and hedge fund activity. Despite short-term financial challenges, the company's revenue growth and operational improvements support its future prospects.
The technical indicators suggest a bullish trend. The MACD is positive and expanding, the RSI is neutral at 58.211, and the moving averages show a bullish alignment (SMA_5 > SMA_20 > SMA_200). Key support levels are at $3.265, with resistance at $4.127 and $4.393, indicating potential upward movement.
FDA rejection of Replimune's RP1 reduces competition for Iovance's Amtagvi in the near term.
Analysts project significant sales growth for Amtagvi, with expectations for annual sales to exceed $1 billion by
Hedge funds are heavily buying the stock, with a 296.59% increase in buying activity last quarter.
Analysts maintain Buy ratings with price targets as high as $16, indicating strong upside potential.
Financial performance shows a decline in net income (-8.47% YoY) and EPS (-30.77% YoY) in Q4
The company remains unprofitable, with a net loss of -$71.9 million in the latest quarter.
Potential competition from other cell therapies could emerge by 2027.
In Q4 2025, revenue increased by 17.74% YoY to $86.77 million, driven by strong sales of Amtagvi. Gross margin improved to 39.35%, up 3.01% YoY, reflecting operational optimization. However, net income dropped to -$71.9 million, and EPS declined to -$0.18, highlighting ongoing profitability challenges.
Analysts are generally bullish on IOVA. Jefferies and Chardan have Buy ratings with price targets of $12 and $16, respectively, citing reduced competition and long-term growth potential for Amtagvi. Barclays raised its price target to $11, while Citizens upgraded the stock to Outperform with a $5 target, noting undervaluation and operational improvements. UBS and Baird remain Neutral but acknowledge improved fundamentals.
